marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2022-Q3
added 11-14-2022
Opiant Pharmaceuticals Balance Sheet 2011-2024 | OPNT
Annual Balance Sheet Opiant Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-36.8 M | -29.3 M | -30.2 M | -24.6 M | -6.87 M | -1.32 M | -434 K | -255 K | -574 K | -69.6 M | -51.8 K |
Long Term Debt |
673 K | 18.7 M | - | - | - | - | - | - | - | 2.74 M | - |
Long Term Debt Current |
338 K | 282 K | 517 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 18.7 M | 255 K | 2.7 M | 2.31 M | 2.35 M | 5.3 M | 1.41 M | 750 K | 10.5 M | 308 K |
Total Current Liabilities |
6.85 M | 6.42 M | 5.61 M | 9.83 M | 5.66 M | 4.24 M | 3.57 M | 1.97 M | 883 K | - | - |
Total Liabilities |
23.6 M | 25.1 M | 5.86 M | 12.5 M | 6.47 M | 6.59 M | 8.87 M | 3.38 M | 1.63 M | 78.3 M | 416 K |
Deferred Revenue |
16.6 K | 355 K | 918 K | 1.21 M | 254 K | 250 K | - | - | - | 47.9 M | - |
Retained Earnings |
-61.7 M | -64.7 M | -62.8 M | -74.4 M | -54.6 M | -61.2 M | -53.4 M | -46.3 M | -28.6 M | 13.7 M | -11.5 M |
Total Assets |
70.4 M | 60.6 M | 40.3 M | 29.4 M | 10.8 M | 1.88 M | 488 K | 301 K | 643 K | 198 M | 77.7 K |
Cash and Cash Equivalents |
37.9 M | 48.3 M | 31 M | 24.6 M | 8.12 M | 1.48 M | 434 K | 255 K | 599 K | 20.4 K | 51.8 K |
Book Value |
46.8 M | 35.5 M | 34.4 M | 16.9 M | 4.33 M | -4.7 M | -8.39 M | -3.08 M | -990 K | 120 M | -339 K |
Total Shareholders Equity |
46.8 M | 35.5 M | 34.4 M | 16.9 M | 13 M | -4.7 M | -8.39 M | -3.08 M | -990 K | -619 K | -339 K |
All numbers in USD currency
Quarterly Balance Sheet Opiant Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 12.3 M | 13.7 M | 13.7 M | 16.1 M | 18.9 M | 18.8 M | 18.8 M | 18.7 M | - | 18.7 M | 18.7 M | 255 K | 255 K | 255 K | 255 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 14.3 M | 16.7 M | 19.6 M | 19.6 M | 18.8 M | 18.7 M | - | 18.7 M | 18.7 M | 255 K | 358 K | 255 K | 255 K | 2.7 M | 402 K | 2.7 M | 2.7 M | 2.12 M | 2.4 M | 2.12 M | 2.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | 21.4 M | 19.2 M | 21.1 M | 23.6 M | 27 M | 25.4 M | 24.9 M | 25.1 M | 25.1 M | 25.1 M | 25.1 M | 5.86 M | 5.86 M | 5.86 M | 5.86 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 7.77 M | 7.77 M | 7.77 M | 7.77 M | 6.23 M | 7.1 M | 6.59 M | 6.59 M | 7.11 M | 9.71 M | 8.87 M | 8.87 M | 2.15 M | 5.34 M | 3.38 M | 3.38 M | 1.2 M | 2.2 M | 1.63 M | 1.63 M | 368 K | 865 K | 664 K | 664 K | - | 270 K | 416 K | 416 K |
Deferred Revenue |
- | - | - | - | 16.6 K | - | - | 859 K | 355 K | 355 K | 355 K | 355 K | 918 K | 918 K | 1.37 M | 757 K | 1.21 M | 660 K | 760 K | 1.21 M | 379 K | 379 K | 379 K | 379 K | - | 250 K | 250 K | 250 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | -95.5 M | -85.6 M | -73.9 M | -61.7 M | -62.4 M | -65.8 M | -67.5 M | -64.7 M | -64.7 M | -64.7 M | -64.7 M | -62.8 M | -62.8 M | -62.8 M | -62.8 M | -74.4 M | -74.4 M | -74.4 M | -74.4 M | -53.2 M | -53.2 M | -53.2 M | -53.2 M | -60.5 M | -61.8 M | -61.2 M | -61.2 M | -49.9 M | -64.5 M | -53.4 M | -53.4 M | - | -47.1 M | -46.3 M | -46.3 M | - | - | -34.9 M | - | - | - | - | - | - | - | - | - |
Total Assets |
- | 42 M | 48.8 M | 60.3 M | 70.4 M | 69 M | 61.8 M | 58.9 M | 60.6 M | 60.6 M | 60.6 M | 60.6 M | 40.3 M | 40.3 M | 40.3 M | 40.3 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 20.8 M | 20.8 M | 20.8 M | 20.8 M | 1.33 M | 1.98 M | 1.88 M | 1.88 M | 1.11 M | 493 K | 488 K | 488 K | 447 K | 1.7 M | 301 K | 301 K | 176 K | 359 K | 643 K | 643 K | 72.8 K | 26.4 K | 45 K | 45 K | - | 38.3 K | 77.7 K | 77.7 K |
Cash and Cash Equivalents |
- | 35.4 M | 40.2 M | 48.3 M | 37.9 M | 35.3 M | 33.4 M | 35.4 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 31 M | 31 M | 31 M | 31 M | 24.6 M | 24.6 M | 24.6 M | 24.6 M | 8.12 M | 8.12 M | 8.12 M | 8.12 M | 13.2 M | 1.18 M | 1.48 M | 1.18 M | 1.06 M | 455 K | 434 K | 455 K | 420 K | 1.15 M | 255 K | 1.15 M | 152 K | 324 K | 599 K | 324 K | 47.4 K | 2.18 K | 20.4 K | 2.18 K | 1.12 K | 12.6 K | 51.8 K | 12.6 K |
Book Value |
- | 20.5 M | 29.6 M | 39.3 M | 46.8 M | 42 M | 36.4 M | 34 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 34.4 M | 34.4 M | 34.4 M | 34.4 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 13 M | 13 M | 13 M | 13 M | -4.9 M | -5.12 M | -4.7 M | -4.7 M | -6 M | -9.22 M | -8.39 M | -8.39 M | -1.7 M | -3.63 M | -3.08 M | -3.08 M | -1.03 M | -1.84 M | -990 K | -990 K | -295 K | -839 K | -619 K | -619 K | - | -231 K | -339 K | -339 K |
Total Shareholders Equity |
- | 20.5 M | 29.6 M | 39.3 M | 46.8 M | 42 M | 36.4 M | 34 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 34.4 M | 34.4 M | 34.4 M | 34.4 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 13 M | 13 M | 13 M | 13 M | -4.9 M | -5.12 M | -4.7 M | -4.7 M | -6 M | -9.22 M | -8.39 M | -8.39 M | -1.7 M | -3.63 M | -3.08 M | -3.08 M | -1.03 M | -1.84 M | -990 K | -990 K | -295 K | -839 K | -619 K | -619 K | - | -231 K | -339 K | -339 K |
All numbers in USD currency